Skip to main content

News and FDA-Alerts

psoriasis0
News
03/19/2026
Jessica Garlewicz
Lysine crotonylation, a post-translational modification previously studied in oncology, may play a role in psoriasis pathogenesis, according to a translational study comparing protein modification profiles in lesional and non-lesional skin.
Lysine crotonylation, a post-translational modification previously studied in oncology, may play a role in psoriasis pathogenesis, according to a translational study comparing protein modification profiles in lesional and non-lesional skin.
Lysine crotonylation, a...
03/19/2026
The Dermatologist
FDA Alerts
03/18/2026
Jessica Garlewicz
The US Food and Drug Administration approved Icotyde (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 years and older.
The US Food and Drug Administration approved Icotyde (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 years and older.
The US Food and Drug...
03/18/2026
The Dermatologist
FDA Alerts
03/17/2026
Jessica Garlewicz
The US Food and Drug Administration approved Cosentyx for the treatment of pediatric patients aged 12 years and older with moderate-to-severe hidradenitis suppurativa.
The US Food and Drug Administration approved Cosentyx for the treatment of pediatric patients aged 12 years and older with moderate-to-severe hidradenitis suppurativa.
The US Food and Drug...
03/17/2026
The Dermatologist
atopic dermatitis
News
03/11/2026
Jessica Garlewicz
Socioeconomic status appears to influence pediatric atopic dermatitis, but the direction and strength of the association remain unclear.
Socioeconomic status appears to influence pediatric atopic dermatitis, but the direction and strength of the association remain unclear.
Socioeconomic status appears to...
03/11/2026
The Dermatologist
FDA Alerts
03/10/2026
Jessica Garlewicz
On March 6, 2026, the US Food and Drug Administration approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis.
On March 6, 2026, the US Food and Drug Administration approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis.
On March 6, 2026, the US Food...
03/10/2026
The Dermatologist
psoriasis
News
03/03/2026
Jessica Garlewicz
Biologic therapy for moderate-to-severe plaque psoriasis was associated with marked improvements in psychological distress and quality of life in a real-world clinical setting.
Biologic therapy for moderate-to-severe plaque psoriasis was associated with marked improvements in psychological distress and quality of life in a real-world clinical setting.
Biologic therapy for...
03/03/2026
The Dermatologist
psoriasis
News
02/03/2026
Jessica Garlewicz
Anxiety and depression symptoms can still occur in young adults with well-controlled psoriasis, even when disease activity is minimal, according to a cross-sectional study exploring psychological distress and its potential biological...
Anxiety and depression symptoms can still occur in young adults with well-controlled psoriasis, even when disease activity is minimal, according to a cross-sectional study exploring psychological distress and its potential biological...
Anxiety and depression symptoms...
02/03/2026
The Dermatologist
psoriasis
News
01/22/2026
Jessica Garlewicz
A new systems biology study using mathematical modeling provides insight into how cytokine imbalance drives psoriasis flares and suggests that restoring immune-epidermal feedback.
A new systems biology study using mathematical modeling provides insight into how cytokine imbalance drives psoriasis flares and suggests that restoring immune-epidermal feedback.
A new systems biology study...
01/22/2026
The Dermatologist
Cutaneous Squamous Cell Carcinoma
News
01/06/2026
Jessica Garlewicz
An updated evidence-based review outlines contemporary strategies for evaluating and managing cutaneous squamous cell carcinoma.
An updated evidence-based review outlines contemporary strategies for evaluating and managing cutaneous squamous cell carcinoma.
An updated evidence-based review...
01/06/2026
The Dermatologist
Atopic dermatitis
FDA Alerts
10/06/2025
Riya Gandhi, MA
On October 6, 2025, the US FDA approved ZORYVE (roflumilast) cream 0.05% for the topical treatment of mild-to-moderate atopic dermatitis in pediatric patients aged 2 to 5 years.
On October 6, 2025, the US FDA approved ZORYVE (roflumilast) cream 0.05% for the topical treatment of mild-to-moderate atopic dermatitis in pediatric patients aged 2 to 5 years.
On October 6, 2025, the US FDA...
10/06/2025
The Dermatologist